<DOC>
	<DOCNO>NCT00724412</DOCNO>
	<brief_summary>Comparison two Dry Eye product</brief_summary>
	<brief_title>Evaluate Artificial Tear Efficacy Moderate Severe Dry Eye</brief_title>
	<detailed_description />
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<criteria>Inclusion : Have score least 2 ( `` time '' ) subjectassessed Symptom Eligibility question ; see Section 8.5.1 . Have sodium fluorescein corneal stain sum ≥ 3 either eye ; see Section 8.5.10 . Have bestcorrected visual acuity 0.6 log MAR good eye assess use ETDRS chart ; see Section 8.5.7 . Exclusion : Have history current evidence following : epithelial herpes simplex keratitis ( dendrictic keratitisis ) ; vaccinia , active recent varicella viral disease cornea and/or conjunctiva ; ocular rosacea ; acute chronic bacterial disease cornea and/or conjunctiva and/or eyelid ; mycobacterial infection eye ; and/or fungal disease eye . Use Restasis® ( cyclosporine ophthalmic emulsion , 0.05 % ) within 30 day Visit 1 . Use systemic medication may contribute dry eye dose regimen stable least 30 day prior Visit Additionally , dose regimen must remain stable throughout study period . Medications know contribute dry eye include , limited , cold allergy treatment , tricyclic antidepressant , hormone replacement therapy . Presence ocular condition active acute blepharitis , conjunctival infection , iritis , ocular condition may preclude safe administration test article . Unwilling discontinue contact lens wear least 7 day prior Visit 1 study period . Current punctal occlusion type ( e.g. , collagen plug , silicone plug ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Dry Eye</keyword>
	<keyword>Corneal Staining</keyword>
</DOC>